VANCOUVER, BC--NovaDx International and its wholly-owned subsidiary Proteomix here entered into an agreement with German chemical and pharmaceutical company Bayer under which NovaDx will identify a series of osteoporosis genes. Bayer will pay up to $3 million to NovaDx based upon the successful completion of research milestones, and NovaDx will give Bayer access to a series of novel osteoclast-specific genes that may be potentially useful as drug targets for metabolic bone disease.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.